About this trial
This study evaluates the feasibility of conducting a larger study on the impact of treating massive hemorrhage with calcium in trauma patients. Patients undergoing the Massive Hemorrhage Protocol (MHP) will be randomly assigned to receive either calcium gluconate or placebo drug after every 4 packs of units of RBCs received during the MHP.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult trauma patients undergoing the MHP at Victoria Hospital, London, Ontario
Disqualifiers
Under the age of 18
Pregnant
Trial design
Parallel
Treatments tested in this trial
calcium gluconate
Drug3g IV or IO calcium gluconate.
Control: Placebo
Drug3g of IV or IO saline placebo.
Treatment groups
Trial outcomes
Primary outcomes
Feasibility
Recruitment of patients, adherence to the protocol, and assessment of any protocol violations that occur during the trial.
Secondary outcomes
Ionized calcium (iCa)
Change in iCa between first iCa measurement during MHP and first iCa measurement after MHP
Total blood product transfused
Number and type of blood products transfused during the MHP
Hemodynamic instability
Mean blood pressure during the MHP
ICU mortality
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead sponsor
London Health Sciences Centre
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: